Publication

The IRA of 2022’s price negotiation provision for drugs continues to be a subject of debate in the healthcare community. During the course of Tapestry healthcare initiatives, the topic of supplemental indication development arose as a potentially unintended consequence of the IRA’s drug price program. This brief provides candid industry perspectives and insights on supplemental indication pursuit in the post-IRA market, as well as potential next steps for consideration by the life sciences community and others.